Devices Fill The Lung Space

Interventional pulmonology may be a specialty device market, but its diseases, including COPD, asthma and lung cancer, are enormous and growing.

New companies in emerging markets are fond of saying that they're operating in a field that's like interventional cardiology was, say, 10 or 15 years ago. That's when minimally invasive diagnostic procedures paved the way for minimally invasive device interventions, some of which are now billion dollar markets. Although it's a cliché, the comparison really does ring true for interventional pulmonology, where 6,000 bronchoscopists have long had the tools for the minimally invasive diagnosis of life-threatening disorders, but no therapeutic tools to go along with them.

Ten years ago, the earliest interventional pulmonology companies sprang up; first came Pulmonx Inc. , followed by Broncus Technologies...

More from Archive

More from Medtech Insight

Execs On The Move: July 14–18, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.